Heart Rhythm
Volume 6, Issue 3, Supplement , Pages S45-S48 , March 2009

Strategies for reducing sudden cardiac death: Application of microvolt T-wave alternans testing in clinical practice

  • Michael J. Mirro, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests and correspondence: Dr. Michael J. Mirro, Parkview Research Center, 2426 East State Street, Fort Wayne, Indiana 46805

References 

  1. Chugh SS, Jui J, Gunson K, et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol. 2004;44:1268–1275
  2. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med. 2001;345:1473–1482
  3. Zipes DP, Wellens HJJ. Sudden cardiac death. Circulation. 1998;98:2334–2351
  4. Albert CM, Chae CU, Grodstein F, et al. Prospective study of sudden cardiac death among women in the United States. Circulation. 2003;107:2096–2101
  5. Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J. 1989;117:151–159
  6. Armoundas AA, Hohnloser SH, Ikeda T, et al. Can microvolt T-wave alternans testing reduce unnecessary defibrillator implantation?. Nat Clin Pract Cardiovasc Med. 2005;2:522–528
  7. Gehi AK, Stein RH, Metz LD, et al. Microvolt T-wave alternans for the risk stratification of ventricular tachyarrhythmic events: a meta-analysis. J Am Coll Cardiol. 2005;46:75–82
  8. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–1583
  9. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297–1302
  10. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748–754
  11. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237
  12. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883
  13. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease (Multicenter Unsustained Tachycardia Trial Investigators). N Engl J Med. 1999;341:1882–1890
  14. Moss AJ, Hall WJ, Cannom DS, et al. Multicenter Automatic Defibrillator Implantation Trial Investigators (Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia). N Engl J Med. 1996;335:1933–1940
  15. Hernandez AF, Fonarow GC, Liang L, et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA. 2007;298:1525–1532
  16. Quan KJ, Amit G, Costantini O. Awareness of referral criteria for implantable defibrillator implantation amongst primary care physicians (abstr). Heart Rhythm. 2008;5:S46
  17. Salvo J, Bersohn MM. ICD referral rate from a cardiomyopathy clinic (abstr). Europace. 2008;10(Suppl 1):i96
  18. Buxton AE, Lee KL, Hafley G, et al. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1150–1157
  19. Goldenberg I, Vyas AK, Hall WJ, et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 2008;51:288–296
  20. Chow T, Kereiakes DJ, Bartone C, et al. Prognostic utility of microvolt T-wave alternans in risk stratification of patients with ischemic cardiomyopathy. J Am Coll Cardiol. 2006;47:1820–1827
  21. Salerno-Uriarte JA, De Ferrari GM, Klersy C, et al. Prognostic value of T-wave alternans in patients with heart failure due to nonischemic cardiomyopathy: results of the ALPHA study. J Am Coll Cardiol. 2007;50:1896–1904
  22. de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, et al. Out-of-hospital cardiac arrest in the 1990s: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol. 1997;30:1500–1505
  23. Myerburg RJ, Mitrani R, Interian A, et al. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. Circulation. 1998;97:1514–1521
  24. Yan AT, Shayne AJ, Brown KA, et al. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation. 2006;114:32–39
  25. Hsia J, Jablonski KA, Rice MM, et al. Sudden cardiac death in patients with stable coronary artery disease and preserved left ventricular systolic function. Am J Cardiol. 2008;101:457–461
  26. Baravelli M, Salerno-Uriarte D, Guzzetti D, et al. Predictive significance for sudden death of microvolt-level T wave alternans in New York Heart Association class II congestive heart failure patients: a prospective study. Int J Cardiol. 2005;105:53–57
  27. Exner DV, Kavanagh KM, Slawnych MP, et al. Noninvasive risk assessment early after a myocardial infarction–the REFINE study. J Am Coll Cardiol. 2007;50:2275–2284
  28. Ikeda T, Yoshino H, Sugi K, et al. Predictive value of microvolt T-wave alternans for sudden cardiac death in patients with preserved cardiac function after acute myocardial infarction: results of a collaborative cohort study. J Am Coll Cardiol. 2006;48:2268–2274
  29. Radoi N, Ionescu DD. Microvolt T wave alternans may be used as a risk stratifier in post myocardial infarction patients without left ventricular systolic dysfunction (abstract). Europace. 2008;10(Suppl 1):i16
  30. Greenberg H, Case RB, Moss AJ, et al. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol. 2004;43:1459–1465

 Dr. Mirro is a consultant with St. Jude Medical and Cambridge Heart, and has Stock ownership in Medtronic and in Cambridge Heart and Life Co.

PII: S1547-5271(09)00003-4

doi: 10.1016/j.hrthm.2009.01.001

Heart Rhythm
Volume 6, Issue 3, Supplement , Pages S45-S48 , March 2009

Article Tools